The global In vitro fertilization market is projected to be valued at USD 505.2 Million in 2017 and is expected to grow at a CAGR of 10.9% to reach to USD 847.8 Million by 2022.
CooperSurgical (US) dominated the In vitro fertilization market in 2017. It has a wide product portfolio of IVF media and assisted reproductive technology. The firm offers fertility products which include lab equipment, culture media, and micro tools. These products find applications in hospitals and surgical centers, obstetricians and gynecologists, medical offices, and fertility clinics. To maintain its leading position and increase its customer base in the in vitro fertilization market, the company mainly focuses on expanding its market presence by adopting growth strategies such as acquisitions. For instance in 2016, CooperSurgical acquired Wallace Pharmaceuticals (India) to further strengthen its existing IVF product portfolio. CooperSurgical has its distribution facilities in Connecticut, Texas, and Denmark, along with diagnostic facilities located in multiple locations including California, Florida, Illinois, Michigan, New Jersey, Oregon, Texas, Canada, and the UK.
Cook Medical (US) held the second position in the In vitro fertilization market in 2017. The company primarily operates in Australia, Canada, Denmark, Ireland, and the U.S., and distributes its products across 135 countries. The company is engaged in manufacturing catheters, incubators, needles, culture media used in the area of reproductive health. The company’s impressive product portfolio is complemented by client support services offered by the firm. The company’s products cater to end users such as fertility clinics, hospitals, and surgical centers.
Vitrolife (Sweden) is another key player of the global In vitro fertilization market in 2017. Vitrolife develops, manufactures, and markets, products for assisted reproduction. Its fertility product area provides nutrient solutions (media) and advanced consumable instruments including needles and pipettes, for the treatment of human infertility. In addition, the company offers a wide range of products for various procedures such as sperm preparation, oocyte retrieval, conventional IVF, ICSI, embryo culture, embryo transfer, vitrification, and slow freezing under its fertility segment. To maintain its leading position, the company focuses on business strategies such as product launches and acquisitions. For instance, in 2016, Vitrolife acquired OCTAX Microscience (Germany). Also, in 2016, the firm launched EmbryoScope+, an imaging system with an integrated incubator. The firm has its presence in the U.S., Denmark, Hungary, Australia, France, Italy, the UK, China, Sweden, and Japan.
Download Free PDF – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89198891
Other players include Thermo Fisher Scientific (US), EMD Sereno (US), Genea Limited (Australia), Esco Micro (Singapore), IVFtech (Denmark), Rocket Medical (UK) ,Nidacon International (Sweden), Lotus Bio (Israel), Eppendorf (Germany), Okolab (Italy), IKS International (Netherlands), Hunter Scientific (UK), Thomas Medical (US), Labotect (Germany), Shivani Scientific (India), Olympus Corporation (Japan), and RI.MOS. (Italy).
Related Reports:
In Vitro Fertilization Market by Product (Imaging System, Incubator, Cabinets, Sperm Separation System, Cryopreservation media, Embryo Culture media), Type of Cycles & End Users (Fertility Clinics and Surgical Centres, Cryobanks) – Global Forecast to 2022
